The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide (Q36655240)

15 August 2017

1 reference

title

The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide (English)

1 reference

15 August 2017

0 references

0 references

Christopher J Fowler

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Fundamental and Clinical Pharmacology

15 August 2017

published in

1 reference

15 August 2017

volume

20

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

549-562

1 reference

Early medical use of cannabis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Evidence for novel cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

In silico patent searching reveals a new cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

N-acylated glycerophospholipids and their derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Molecular characterization of a phospholipase D generating anandamide and its congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Endocannabinoids control the induction of cerebellar LTD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Development of the first potent and specific inhibitors of endocannabinoid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The expanding field of cannabimimetic and related lipid mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Chemical constituents of marijuana: the complex mixture of natural cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cannabidiol: an overview of some pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Emerging properties of cannabinoid medicines in management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cannabinoids in the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cannabinoids: between neuroprotection and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Endocannabinoids in the regulation of appetite and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Brain monoglyceride lipase participating in endocannabinoid inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Oxidative metabolism of endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

A role for endocannabinoids in indomethacin-induced spinal antinociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Formation and inactivation of endogenous cannabinoid anandamide in central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Is there a temperature-dependent uptake of anandamide into cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Evidence against the presence of an anandamide transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Further evidence for the existence of a specific process for the membrane transport of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Effect of an unstirred layer on the membrane permeability of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Functional role of high-affinity anandamide transport, as revealed by selective inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Novel selective and metabolically stable inhibitors of anandamide cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Identification of a high-affinity binding site involved in the transport of endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Development of the first potential covalent inhibitors of anandamide cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Membrane transport of anandamide through resealed human red blood cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

N-Myristoylethanolamine-cholesterol (1:1) complex: first evidence from differential scanning calorimetry, fast-atom-bombardment mass spectrometry and computational modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Accumulation of anandamide: evidence for cellular diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Cellular accumulation of anandamide: consensus and controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Structure-based design of a FAAH variant that discriminates between the N-acyl ethanolamine and taurine families of signaling lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The endogenous cannabinoid system protects against colonic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Functional disassociation of the central and peripheral fatty acid amide signaling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Fatty acid amide hydrolase controls mouse intestinal motility in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Modulation of anxiety through blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Molecular cues to implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Fatty acid amide hydrolase deficiency limits early pregnancy events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

A missense mutation in human fatty acid amide hydrolase associated with problem drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Recent developments in cannabinoid ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Structural determinants for recognition and translocation by the anandamide transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The anandamide transport inhibitor AM404 activates vanilloid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

AM-404 elevates renal intracellular Ca(2+), questioning its selectivity as a pharmacological tool for investigating the anandamide transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

The endocannabinoid signaling system: pharmacological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00442.X

10.1111/J.1472-8206.2006.00442.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference